SELLAS Life Sciences Group, Inc.

NasdaqCM:SLS Stock Report

Market Cap: US$2.7b

SELLAS Life Sciences Group Future Growth

Future criteria checks 5/6

SELLAS Life Sciences Group is forecast to grow earnings and revenue by 63.5% and 67.2% per annum respectively while EPS is expected to grow by 64.5% per annum.

Key information

63.5%

Earnings growth rate

64.45%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate67.2%
Future return on equityn/a
Analyst coverage

Low

Last updated13 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jun 30

Why Sellas Remains A Strong Sell After Doubling In Price

Summary Sellas Life Sciences has nearly doubled in value, yet fundamentals remain unchanged and do not justify its $2.5B–$3B valuation. The REGAL trial is a high-risk, binary event with a challenging efficacy bar, and delayed events likely reflect stronger control arm performance, not GPS benefit. Even with REGAL success, the AML CR2 market opportunity is niche, making SLS overvalued even on optimistic risk-adjusted NPV assumptions. I maintain a Strong Sell rating on SLS due to asymmetric risk: I think downside on failure is severe, while upside on success is already priced in. Read the full article on Seeking Alpha
Analysis Article • Jun 17

SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing

Why the new shelf registration matters for SELLAS Life Sciences Group stock SELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common shares, an event that puts potential future capital raising firmly on investors’ radar. The filing follows recent shareholder meetings that backed board proposals and an expanded equity plan. This development sets the stage for possible use of this shelf as SELLAS funds its late stage oncology programs and...
Analysis Article • Oct 08

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 25

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 23

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 18

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jul 13

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 20

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Earnings and Revenue Growth Forecasts

NasdaqCM:SLS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028102-8N/AN/A1
12/31/202744-27N/AN/A1
12/31/2026N/A-37N/AN/A1
3/31/2026N/A-29-28-28N/A
12/31/2025N/A-27-28-28N/A
9/30/2025N/A-26-31-31N/A
6/30/2025N/A-26-31-31N/A
3/31/2025N/A-27-34-34N/A
12/31/2024N/A-31-35-35N/A
9/30/2024N/A-32-33-33N/A
6/30/2024N/A-34-35-32N/A
3/31/2024N/A-36-36-30N/A
12/31/2023N/A-37-37-31N/A
9/30/2023N/A-38-37-32N/A
6/30/2023N/A-36-33-31N/A
3/31/2023N/A-36-33-29N/A
12/31/20221-41-28-24N/A
9/30/20221-39-28-24N/A
6/30/20221-39-28-24N/A
3/31/20223-35-23-23N/A
12/31/20218-21-26-26N/A
9/30/202110-18-18-18N/A
6/30/202110-15-15-15N/A
3/31/20218-15-14-14N/A
12/31/20202-17-10-10N/A
9/30/2020N/A-21-18-18N/A
6/30/2020N/A-28-18-18N/A
3/31/2020N/A-27-19-19N/A
12/31/2019N/A-28N/A-18N/A
9/30/2019N/A-34N/A-18N/A
6/30/2019N/A-32N/A-28N/A
3/31/2019N/A-36N/A-30N/A
12/31/2018N/A-41N/A-30N/A
9/30/2018N/A-37N/A-28N/A
6/30/2018N/A-32N/A-16N/A
3/31/2018N/A-30N/A-13N/A
12/31/2017N/A-24N/A-11N/A
9/30/2017N/A-21N/A-14N/A
6/30/2017N/A-23N/A-16N/A
3/31/2017N/A-20N/A-14N/A
12/31/2016N/A-18N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: SLS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SLS is expected to become profitable in the next 3 years.

Revenue vs Market: SLS's revenue (67.2% per year) is forecast to grow faster than the US market (12.8% per year).

High Growth Revenue: SLS's revenue (67.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SLS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/01 22:22
End of Day Share Price 2026/07/01 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SELLAS Life Sciences Group, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Aydin HuseynovLadenburg Thalmann & Company
Jason McCarthyMaxim Group